Guardant Health, Inc. (GH)
| Previous Close | 21.62 |
| Open | 21.38 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 20.86 - 21.53 |
| 52 Week Range | 15.81 - 37.04 |
| Volume | |
| Avg. Volume | 2,238,670 |
| Market Cap | 2.574B |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.11 |
| Earnings Date | Nov 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.79 |
Business WireGuardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
PALO ALTO, Calif., October 15, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Business WireGOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
PALO ALTO, Calif., September 18, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the peer-reviewed journal Nature Medicine published results from the SCRUM-Japan GOZILA study confirming that selecting targeted therapy on the basis of Guardant360® CDx liquid biopsy results may significantly extend survival for patients with advanced cancer.
